Company news

Myriad Genetics, Inc. news in 2022

Myriad Genetics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

December 18, 2022

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

December 7, 2022

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

November 28, 2022

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

November 16, 2022

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

November 13, 2022

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

November 9, 2022

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

November 2, 2022

Myriad Genetics Reports Third Quarter Financial Results

October 31, 2022

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

October 31, 2022

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

October 30, 2022

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

October 25, 2022

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

September 27, 2022

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

August 30, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

August 24, 2022

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

August 15, 2022

Myriad Genetics Reports Second Quarter Financial Results

August 3, 2022

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

July 27, 2022

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

July 18, 2022

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

July 11, 2022

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

June 27, 2022

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

June 22, 2022

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

June 8, 2022

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

May 25, 2022

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

May 4, 2022

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

May 3, 2022

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

May 2, 2022

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

April 27, 2022

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

April 25, 2022

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

March 13, 2022

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

March 10, 2022

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

March 7, 2022

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

March 1, 2022

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

February 23, 2022

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

February 22, 2022

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

February 15, 2022

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

February 13, 2022

Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

January 4, 2022

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

January 3, 2022

Calls in 2022

Decks in 2022